Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Unknown

EIKN
$10.64 (- $0.92 - 7.96%)
Last updated: Previous Close (2026-05-19)
EIKN Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
Sector N/A
Industry N/A
ISINN/A
Market Price10.64
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend Frequency N/A
P/E RatioN/A
EPSN/A
Market CapN/A
Book ValueN/A
Price to BookN/A
BetaN/A
52w HighN/A
52w LowN/A
Next Earnings DateN/A
About the Company
N/A
Price History
Latest News for EIKN
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitorSix abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
Jennifer Garner’s Once Upon a Farm Rises Nearly 20% to Wrap Up Busy Week for IPOs
Jennifer Garner’s Sidney Bristow character from the TV show Alias and Elektra in Marvel movies may have faced formidable foes. Garner is a co-founder and investor in the organic baby food company Once Upon a Farm which began trading Friday after a rocky week for the market and initial public offerings. Once Upon a Farm priced the IPO at $18, the midpoint of its expected range.
This Mobile App Marketing Firm Is Holding Off an IPO for Now
Liftoff Mobile has postponed its initial public offering, citing market conditions after another day of sharp declines in stocks. “Given current market conditions, we have made a business decision to take additional time before listing,” the company said in a statement emailed to Barron’s. “We are encouraged by the strong interest and positive feedback we have received from investors.” Stocks of peer companies such as AppLovin and Unity Software have fallen along with the tech sector in recent weeks, pressured by concerns over how artificial intelligence is going to transform the industry.